<?xml version="1.0" encoding="UTF-8"?>
<p>Two candidates are currently in Phase II clinical trials. The first one is a recombinant measles virus encoding the CHIKV structural proteins. The first results of the Phase II trial are very encouraging with all vaccines fully immunized after two injections (regardless of the individualâ€™s immunological status against measles virus) and excellent safety and tolerability [
 <xref rid="B209-microorganisms-07-00133" ref-type="bibr">209</xref>]. The second candidate is a VLP vaccine containing CHIKV structural proteins that is immunogenic and protective against a challenge infection in mice and rhesus macaques [
 <xref rid="B214-microorganisms-07-00133" ref-type="bibr">214</xref>]. A Phase I clinical trial confirmed immunogenicity in humans after two injections and the absence of serious adverse events [
 <xref rid="B221-microorganisms-07-00133" ref-type="bibr">221</xref>,
 <xref rid="B222-microorganisms-07-00133" ref-type="bibr">222</xref>]; a Phase II trial is currently underway.
</p>
